Will DigitalOcean Stock Bounce Back?
DigitalOcean (NYSE:DOCN) has run into the proverbial brick wall with…
Sell
27
SOLTF Quote, Financials, Valuation and Earnings
Last price:
$5.91
Seasonality move
:
5.42%
Day range:
$5.91 - $5.91
52-week range:
$5.54 - $10.67
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
2.96x
P/B ratio:
1.19x
Volume:
--
Avg. volume:
--
1-year change:
-33.74%
Market cap:
$531.3M
Revenue:
$190.6M
EPS (TTM):
-$0.42
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
SOLTF
Nxera Pharma
|
-- | -- | -- | -- | -- |
|
AMGXF
AnGes
|
-- | -- | -- | -- | -- |
|
HLOSF
Healios KK
|
-- | -- | -- | -- | -- |
|
PPTDF
PeptiDream
|
-- | -- | -- | -- | -- |
|
SNBIF
SanBio
|
-- | -- | -- | -- | -- |
|
TAK
Takeda Pharmaceutical
|
$7.6B | -- | 2.48% | -- | $17.11 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
SOLTF
Nxera Pharma
|
$5.91 | -- | $531.3M | -- | $0.00 | 0% | 2.96x |
|
AMGXF
AnGes
|
$0.36 | -- | $117.8M | -- | $0.00 | 0% | 22.97x |
|
HLOSF
Healios KK
|
$2.25 | -- | $228.3M | -- | $0.00 | 0% | 54.40x |
|
PPTDF
PeptiDream
|
$13.53 | -- | $1.8B | 16.80x | $0.00 | 0% | 5.80x |
|
SNBIF
SanBio
|
$6.55 | -- | $471.7M | -- | $0.00 | 0% | 113.78x |
|
TAK
Takeda Pharmaceutical
|
$14.57 | $17.11 | $45.5B | 66.77x | $0.33 | 4.24% | 1.56x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
SOLTF
Nxera Pharma
|
48.1% | 1.902 | 78.18% | 2.83x |
|
AMGXF
AnGes
|
-- | 1.309 | -- | 1.28x |
|
HLOSF
Healios KK
|
51.17% | -2.492 | 6.95% | 1.11x |
|
PPTDF
PeptiDream
|
25.74% | 0.548 | 5.48% | 4.62x |
|
SNBIF
SanBio
|
-- | -1.375 | -- | -- |
|
TAK
Takeda Pharmaceutical
|
39.43% | -0.250 | 64.47% | 0.45x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
SOLTF
Nxera Pharma
|
$33M | -$14.4M | -4.28% | -8.65% | -28.7% | -$14.8M |
|
AMGXF
AnGes
|
$368.5K | -$8.2M | -33.92% | -33.92% | -741.83% | -- |
|
HLOSF
Healios KK
|
$59K | -$4.9M | -85.83% | -196.15% | -1239.47% | -$5.1M |
|
PPTDF
PeptiDream
|
$9.6M | -$9M | 23.58% | 34.1% | -29.18% | -$69.4M |
|
SNBIF
SanBio
|
-- | -$6.2M | -- | -- | -- | -$10.9M |
|
TAK
Takeda Pharmaceutical
|
$4.4B | -$491.4M | 0.89% | 1.49% | -5.41% | $854.8M |
Nxera Pharma vs. Competitors
-
Which has Higher Returns SOLTF or AMGXF?
AnGes has a net margin of -11.44% compared to Nxera Pharma's net margin of -737.34%. Nxera Pharma's return on equity of -8.65% beat AnGes's return on equity of -33.92%.
Company Gross Margin Earnings Per Share Invested Capital SOLTFNxera Pharma75.69% -$0.06 $863.6M AMGXFAnGes33.2% -$0.03 $21.5M -
What do Analysts Say About SOLTF or AMGXF?
Nxera Pharma has a consensus price target of --, signalling downside risk potential of --. On the other hand AnGes has an analysts' consensus of -- which suggests that it could fall by --. Given that Nxera Pharma has higher upside potential than AnGes, analysts believe Nxera Pharma is more attractive than AnGes.
Company Buy Ratings Hold Ratings Sell Ratings SOLTFNxera Pharma0 0 0 AMGXFAnGes0 0 0 -
Is SOLTF or AMGXF More Risky?
Nxera Pharma has a beta of 0.364, which suggesting that the stock is 63.648% less volatile than S&P 500. In comparison AnGes has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock SOLTF or AMGXF?
Nxera Pharma has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. AnGes offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Nxera Pharma pays -- of its earnings as a dividend. AnGes pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SOLTF or AMGXF?
Nxera Pharma quarterly revenues are $43.6M, which are larger than AnGes quarterly revenues of $1.1M. Nxera Pharma's net income of -$5M is higher than AnGes's net income of -$8.2M. Notably, Nxera Pharma's price-to-earnings ratio is -- while AnGes's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Nxera Pharma is 2.96x versus 22.97x for AnGes. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SOLTFNxera Pharma2.96x -- $43.6M -$5M AMGXFAnGes22.97x -- $1.1M -$8.2M
-
Which has Higher Returns SOLTF or HLOSF?
Healios KK has a net margin of -11.44% compared to Nxera Pharma's net margin of -6742.11%. Nxera Pharma's return on equity of -8.65% beat Healios KK's return on equity of -196.15%.
Company Gross Margin Earnings Per Share Invested Capital SOLTFNxera Pharma75.69% -$0.06 $863.6M HLOSFHealios KK23.68% -$0.18 $26.9M -
What do Analysts Say About SOLTF or HLOSF?
Nxera Pharma has a consensus price target of --, signalling downside risk potential of --. On the other hand Healios KK has an analysts' consensus of -- which suggests that it could fall by --. Given that Nxera Pharma has higher upside potential than Healios KK, analysts believe Nxera Pharma is more attractive than Healios KK.
Company Buy Ratings Hold Ratings Sell Ratings SOLTFNxera Pharma0 0 0 HLOSFHealios KK0 0 0 -
Is SOLTF or HLOSF More Risky?
Nxera Pharma has a beta of 0.364, which suggesting that the stock is 63.648% less volatile than S&P 500. In comparison Healios KK has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock SOLTF or HLOSF?
Nxera Pharma has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Healios KK offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Nxera Pharma pays -- of its earnings as a dividend. Healios KK pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SOLTF or HLOSF?
Nxera Pharma quarterly revenues are $43.6M, which are larger than Healios KK quarterly revenues of $249.2K. Nxera Pharma's net income of -$5M is higher than Healios KK's net income of -$16.8M. Notably, Nxera Pharma's price-to-earnings ratio is -- while Healios KK's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Nxera Pharma is 2.96x versus 54.40x for Healios KK. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SOLTFNxera Pharma2.96x -- $43.6M -$5M HLOSFHealios KK54.40x -- $249.2K -$16.8M
-
Which has Higher Returns SOLTF or PPTDF?
PeptiDream has a net margin of -11.44% compared to Nxera Pharma's net margin of -24.41%. Nxera Pharma's return on equity of -8.65% beat PeptiDream's return on equity of 34.1%.
Company Gross Margin Earnings Per Share Invested Capital SOLTFNxera Pharma75.69% -$0.06 $863.6M PPTDFPeptiDream34.69% -$0.05 $493M -
What do Analysts Say About SOLTF or PPTDF?
Nxera Pharma has a consensus price target of --, signalling downside risk potential of --. On the other hand PeptiDream has an analysts' consensus of -- which suggests that it could fall by --. Given that Nxera Pharma has higher upside potential than PeptiDream, analysts believe Nxera Pharma is more attractive than PeptiDream.
Company Buy Ratings Hold Ratings Sell Ratings SOLTFNxera Pharma0 0 0 PPTDFPeptiDream0 0 0 -
Is SOLTF or PPTDF More Risky?
Nxera Pharma has a beta of 0.364, which suggesting that the stock is 63.648% less volatile than S&P 500. In comparison PeptiDream has a beta of 0.547, suggesting its less volatile than the S&P 500 by 45.312%.
-
Which is a Better Dividend Stock SOLTF or PPTDF?
Nxera Pharma has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. PeptiDream offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Nxera Pharma pays -- of its earnings as a dividend. PeptiDream pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SOLTF or PPTDF?
Nxera Pharma quarterly revenues are $43.6M, which are larger than PeptiDream quarterly revenues of $27.8M. Nxera Pharma's net income of -$5M is higher than PeptiDream's net income of -$6.8M. Notably, Nxera Pharma's price-to-earnings ratio is -- while PeptiDream's PE ratio is 16.80x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Nxera Pharma is 2.96x versus 5.80x for PeptiDream. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SOLTFNxera Pharma2.96x -- $43.6M -$5M PPTDFPeptiDream5.80x 16.80x $27.8M -$6.8M
-
Which has Higher Returns SOLTF or SNBIF?
SanBio has a net margin of -11.44% compared to Nxera Pharma's net margin of --. Nxera Pharma's return on equity of -8.65% beat SanBio's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital SOLTFNxera Pharma75.69% -$0.06 $863.6M SNBIFSanBio-- -$0.08 -- -
What do Analysts Say About SOLTF or SNBIF?
Nxera Pharma has a consensus price target of --, signalling downside risk potential of --. On the other hand SanBio has an analysts' consensus of -- which suggests that it could fall by --. Given that Nxera Pharma has higher upside potential than SanBio, analysts believe Nxera Pharma is more attractive than SanBio.
Company Buy Ratings Hold Ratings Sell Ratings SOLTFNxera Pharma0 0 0 SNBIFSanBio0 0 0 -
Is SOLTF or SNBIF More Risky?
Nxera Pharma has a beta of 0.364, which suggesting that the stock is 63.648% less volatile than S&P 500. In comparison SanBio has a beta of -0.476, suggesting its less volatile than the S&P 500 by 147.611%.
-
Which is a Better Dividend Stock SOLTF or SNBIF?
Nxera Pharma has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. SanBio offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Nxera Pharma pays -- of its earnings as a dividend. SanBio pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SOLTF or SNBIF?
Nxera Pharma quarterly revenues are $43.6M, which are larger than SanBio quarterly revenues of --. Nxera Pharma's net income of -$5M is higher than SanBio's net income of -$5.8M. Notably, Nxera Pharma's price-to-earnings ratio is -- while SanBio's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Nxera Pharma is 2.96x versus 113.78x for SanBio. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SOLTFNxera Pharma2.96x -- $43.6M -$5M SNBIFSanBio113.78x -- -- -$5.8M
-
Which has Higher Returns SOLTF or TAK?
Takeda Pharmaceutical has a net margin of -11.44% compared to Nxera Pharma's net margin of -9.79%. Nxera Pharma's return on equity of -8.65% beat Takeda Pharmaceutical's return on equity of 1.49%.
Company Gross Margin Earnings Per Share Invested Capital SOLTFNxera Pharma75.69% -$0.06 $863.6M TAKTakeda Pharmaceutical63.73% -$0.21 $76.5B -
What do Analysts Say About SOLTF or TAK?
Nxera Pharma has a consensus price target of --, signalling downside risk potential of --. On the other hand Takeda Pharmaceutical has an analysts' consensus of $17.11 which suggests that it could grow by 17.46%. Given that Takeda Pharmaceutical has higher upside potential than Nxera Pharma, analysts believe Takeda Pharmaceutical is more attractive than Nxera Pharma.
Company Buy Ratings Hold Ratings Sell Ratings SOLTFNxera Pharma0 0 0 TAKTakeda Pharmaceutical3 1 0 -
Is SOLTF or TAK More Risky?
Nxera Pharma has a beta of 0.364, which suggesting that the stock is 63.648% less volatile than S&P 500. In comparison Takeda Pharmaceutical has a beta of 0.259, suggesting its less volatile than the S&P 500 by 74.114%.
-
Which is a Better Dividend Stock SOLTF or TAK?
Nxera Pharma has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Takeda Pharmaceutical offers a yield of 4.24% to investors and pays a quarterly dividend of $0.33 per share. Nxera Pharma pays -- of its earnings as a dividend. Takeda Pharmaceutical pays out 280.28% of its earnings as a dividend.
-
Which has Better Financial Ratios SOLTF or TAK?
Nxera Pharma quarterly revenues are $43.6M, which are smaller than Takeda Pharmaceutical quarterly revenues of $6.9B. Nxera Pharma's net income of -$5M is higher than Takeda Pharmaceutical's net income of -$676.5M. Notably, Nxera Pharma's price-to-earnings ratio is -- while Takeda Pharmaceutical's PE ratio is 66.77x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Nxera Pharma is 2.96x versus 1.56x for Takeda Pharmaceutical. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SOLTFNxera Pharma2.96x -- $43.6M -$5M TAKTakeda Pharmaceutical1.56x 66.77x $6.9B -$676.5M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Where Will Cognizant Stock Be In 5 Years?
Cognizant Technologies (NASDAQ:CTSH) is a global provider of IT services…
NVIDIA vs Broadcom Stock: Which Is Best?
NVIDIA (NASDAQ:NVDA) and Broadcom (NASDAQ:AVGO) are two of the hottest…
Stock Ideas
Buy
65
Is MSFT Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 38x
Buy
65
Is NVDA Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 45x
Sell
33
Is AAPL Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 32x
Alerts
Buy
60
MRUS alert for May 24
Merus NV [MRUS] is up 32.55% over the past day.
Buy
57
RGC alert for May 24
Regencell Bioscience Holdings [RGC] is up 28.43% over the past day.
Buy
90
OKLO alert for May 24
Oklo [OKLO] is up 23.11% over the past day.
